abstract: OBJECTIVE: To analysis the relationship between @entity5381 (CB). METHOD: Analysis the paranasal sinus coronal plane CT scans of 972 @entity1 ,observe the incidence of @entity5381 and @entity17651 and classify them into @entity9009 and lower septal deviation. Measure the septal deviation angle and transverse diameter of the @entity17651 , and a nalysis the relationship between @entity5381 . RESULT: The incidences of @entity17651 was 17.03% of 182 @entity1 with @entity5381 and was 14.05% of 790 @entity1 without @entity5381 . There was no statistically difference between them(P > 0.05). The incidences of @entity17651 were 33.33% and 9.02% of the @entity1 with @entity9009 and lower septal deviation, and the difference was statistical (P < 0.01). The mean of the septal deviation angle was 14.55 degrees +/- 3.61 degrees, and the transverse diameter of the @entity17651 was (5.93 +/- 1.88) mm in 20 @entity1 with @entity9009 and CB. The mean of the septal deviation angle was 13.36 degrees +/- 2.42 degrees, and the transverse diameter of the @entity17651 was (4.86 +/- 1.40) mm in 11 @entity1 with lower septal deviation and CB. There was no statistically difference between the septal deviation angle and the transverse diameter of @entity17651 (P > 0.05). CONCLUSION: There was a significant relationship between upper nasal septal devia tion and @entity17651 , especially finding @entity17651 in concave sides of nasal sep turn. But there was no significant relationship between the septal deviation angle and the size of the @entity17651 .

title: [Relationship between XXXX ].

entities_list: @entity17651 :: ('MESH:C563065', 'Disease') :: ['bulbous type concha bullosa']

entities_list: @entity9009 :: ('MESH:D018658', 'Disease') :: ['upper septal deviation']

entities_list: @entity5381 :: ('MESH:D061270', 'Disease') :: ['nasal septal deviation and the bulbous type concha bullosa', 'nasal septal deviation']

answer: @entity5381 :: (MESH:D061270,Disease) :: ['nasal septal deviation and the bulbous type concha bullosa']


abstract: OBJECTIVE: @entity3747 is one of the principal complications of total or completion thyroidectomy. A number of different protocols for managing this potential complication have been published. Our simple postoperative regimen is described and the safety and cost-effectiveness assessed. STUDY DESIGN: Case series with planned data collection. SETTING: Academic medical center. SUBJECTS AND METHODS: All @entity1 undergoing total or completion thyroidectomy from January 2008 through June 2010 were evaluated. Data collected included age; gender; procedure performed; levels of ionized @entity460 , parathyroid hormone, and @entity560 ; complications; and need for readmission. Standard descriptive statistics were used to summarize these data. RESULTS: In total, 526 @entity1 had thyroid surgery during the 30-month study period. Of these, 307 underwent completion or total thyroidectomy and were prescribed a 3-week tapering course of @entity4959 postoperatively. Twenty-three @entity1 (7.5%) experienced symptoms of @entity3747 that were managed on an outpatient basis with additional doses of oral @entity460 . Two @entity1 (0.7%) required readmission. The cost of a 3-week regimen of @entity4959 is approximately  15. This is considerably less expensive than either the cost of overnight admission or published laboratory protocols that are designed to predict the risk of @entity3747 . CONCLUSIONS: Prophylactic @entity460 supplementation without routine laboratory assessment proved to be a safe and cost-effective method of preventing and managing postoperative @entity3747 following total or completion thyroidectomy.

title: XXXX management after thyroidectomy: a simple and cost-effective method.

entities_list: @entity3747 :: ('MESH:D006996', 'Disease') :: ['Hypocalcemia', 'hypocalcemia']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4959 :: ('MESH:D002119', 'Chemical') :: ['calcium carbonate']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']

answer: @entity460 :: (MESH:D002118,Chemical) :: ['Calcium']


abstract: Many quality-of-care and risk prediction metrics rely on time to first rehospitalization even though @entity712 ( @entity712 ) @entity1 may undergo several repeat hospitalizations. The aim of this study is to compare repeat hospitalization models. Using a population-based cohort of 40,667 @entity1 , we examined both @entity712 and all cause re-hospitalizations using up to five years of follow-up. Two models were examined: the gap-time model which estimates the adjusted time between hospitalizations and a multistate model which considered @entity1 to be in one of four states; community-dwelling, in hospital for @entity712 , in hospital for any reason, or dead. The transition probabilities and times were then modeled using @entity1 characteristics and number of repeat hospitalizations. We found that during the five years of follow-up roughly half of the @entity1 returned for a subsequent hospitalization for each repeat hospitalization. Additionally, we noted that the unadjusted time between hospitalizations was reduced    40% between each successive hospitalization. After adjustment each additional hospitalization was associated with a 28 day (95% CI: 22-35) reduction in time spent out of hospital. A similar pattern was seen when considering the four state model. A large proportion of @entity1 had multiple repeat hospitalizations. Extending the gap between hospitalizations should be an important goal of treatment evaluation.

title: XXXX re-admission: measuring the ever shortening gap between repeat @entity712 hospitalizations.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['HF', 'heart failure']

answer: @entity712 :: (MESH:D006333,Disease) :: ['Heart failure']


abstract: BACKGROUND: In 2014, liquid-based cytology with HPV triage replaced conventional cytology. The aim of our study was to compare conventional and liquid-based cytology (LBC), estimate the prevalence of abnormal cervical cytology and high risk HPV (hrHPV) @entity281 and their correlation, among screened @entity1 in Luxembourg. METHODS: Between the first January 2013 and 31st December 2015, 315,868 cervical samples from 150,815 @entity1 (mean age 42.2  years) were investigated by the national cytology laboratory. Slides were prepared and screened according to European Guidelines. All cytological results were classified according to the Bethesda 2001 system terminology. RESULTS: The prevalence of @entity66 was as follows: atypical squamous cells of undetermined significance (ASC-US), 1.3%; low-grade squamous @entity75 (LSIL), 1.9%; @entity2784 ( @entity2784 ), 0.4%. The detection rate of cytological lesions was significantly higher with LBC than with conventional cytology. Based on 11,838 samples with concomitant cytology and HPV testing, hrHPV was detected in 9.5, 45.3, 70.0, and 92.6% of @entity1 with negative cytology, ASC-US, LSIL, and @entity2784 , respectively. CONCLUSION: More @entity75 were identified using LBC compared to conventional cytology. @entity281 was correlated with the severity of @entity75 . The current findings provide important information to evaluate the prevention of @entity5 in Luxembourg and for monitoring the future impact of HPV vaccination. Diagn. Cytopathol. 2017.    2017 Wiley Periodicals, Inc.

title: Introduction of liquid-based cytology and human papillomavirus testing in XXXX screening in luxembourg.

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['abnormal cervical lesions']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['intraepithelial lesion', 'cervical lesions', 'intraepithelial lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['HrHPV infection', 'infection']

entities_list: @entity2784 :: ('MESH:D065310', 'Disease') :: ['HSIL', 'high-grade squamous intraepithelial lesion']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: In @entity1 with @entity191 ( @entity191 ), tetrapolar electrodes were implanted in the prelemniscal radiations (RAPRL) to treat @entity400 , @entity2003 and @entity2845 . Fifteen @entity1 were implanted unilaterally and five @entity1 bilaterally and followed-up for one year. The selection criteria included the presence of unilateral pronounced @entity400 and @entity2003 in @entity1 implanted unilaterally or bilateral symptoms including severe @entity2845 in @entity1 implanted bilaterally. In the operating room, the @entity400 decreased significantly or was abolished following the insertion of the electrode in the RAPRL. This effect was temporary and subsided when the stimulation was off. However, when the stimulator was turned on, the severity of the symptoms and signs decreased significantly. The post-implantation MRI confirmed that the electrode contacts used for stimulation were inserted in RAPRL, a group of fibers located between the red nucleus and subthalamic nucleus, above the substantia nigra, medially to the zona incerta and below the thalamus. The @entity1 were evaluated using the UPDRS part III, before implantation and every 3 months during the first year. Global scores decreased significantly. The pre- and postoperative median values (range in round brackets) were as follows: @entity400 improved from 3 (2-16) to 1 (2-3) (p<0.001); @entity2003 was either abolished or decreased markedly from 2 (1-16) to 0 (0-4) (p< 0.001); @entity2845 improved from 2 (0-4) to 1 (0-2) (p<0.001). We conclude that RAPRL, an area anatomically different from @entity9221 , is a good target for electrical stimulation in order to treat effectively all the main symptoms of @entity191 .

title: Neuromodulation of prelemniscal radiations in the treatment of XXXX .

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD']

entities_list: @entity2845 :: ('MESH:D018476', 'Disease') :: ['bradykinesia']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: In the coming years, basic science research into the mechanisms of @entity46 development and persistence almost certainly will open new avenues for treatment. A wide armamentarium of medical therapies already exists, however. The efficacy of most of these methods in reducing @entity158 is well established. The choice of which to use depends largely on @entity1 preference after an appropriate discussion of risks, side effects, and cost. Typically, oral contraceptives and NSAIDs are first-line therapy because of their low cost and mild side effects (Box 6). Because of its greater potential for suppressing endometrial development, consideration should be given to prescribing a low-dose monophasic oral contraceptive continuously. If adequate relief is not obtained or if side effects prove intolerable, consideration should be given to the use of @entity7828 (oral, intramuscular, or IUD) or a GnRH agonist with immediate add-back therapy. @entity7828 are less expensive, but @entity1176 agonists with add-back may be better tolerated. If none of these medications proves beneficial or if side effects are too pronounced, then repeat surgery is warranted. The surgery may have analgesic value and serves to reconfirm the diagnosis. Finally, if @entity46 is identified at the time of surgery, then consideration should be given to prescribing medical therapy postoperatively.

title: Medical management of XXXX .

entities_list: @entity7828 :: ('MESH:D011372', 'Chemical') :: ['Progestins', 'progestins']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['endometriosis-associated pain']

answer: @entity158 :: (MESH:D010146,Disease) :: ['endometriosis-associated pain']


abstract: In a retrospective case-control review, we evaluated @entity3459 testing in @entity1 undergoing major noncardiac operations to determine if routine testing benefits this group of @entity1 . The platelet count (PC), @entity556 time (PT), and activated partial thromboplastin time (aPTT) in all @entity1 undergoing major noncardiac surgery over a 22-month period were reviewed. The review was done both manually and by the computerized hospital information system. Major surgery was defined as procedures usually associated with significant @entity548 . For each @entity1 with abnormal results, another two control @entity1 undergoing the same surgery and matched for age and gender were identified. Case and control @entity1 were compared regarding a change in the management plan, use of blood products, @entity190 , and @entity548 complications by detailed chart review. A total of 828 @entity1 undergoing nine different surgeries were reviewed. The incidence of abnormal PCs was 2.2% [95% confidence interval (CI) 1.2-3.2%] and that of abnormal PT/aPTTs was 2.1% (95% CI 1.1-3.1%). There were only two cases each of @entity882 and prolonged PT/aPTT where the coagulation tests were not indicated clinically. Although (compared to controls) @entity1 with abnormal tests had more changes in their anesthesia plan (36% vs. 2%, p < 0.001) and platelet or fresh frozen plasma transfusions (50% vs. 9%, p < 0.001), @entity190 and the incidence of @entity548 complications were not different. We conclude that the use of @entity3459 tests in @entity1 undergoing major noncardiac surgery should still be guided by clinical assessment. The surgical procedure itself does not constitute an indication for testing.

title: Value of XXXX tests: reappraisal of major noncardiac surgery.

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity3459 :: ('MESH:D025861', 'Disease') :: ['preoperative coagulation']

answer: @entity3459 :: (MESH:D025861,Disease) :: ['preoperative coagulation']


abstract: OBJECTIVE: The aims of this study were (1) to explore whether the experience at the Radcliffe Infirmary (Oxford, UK) supported the use of combined approach tympanoplasty for @entity3540 , by determining the rate of disease at subsequent surgery, and (2) to assess whether this rate differed from findings reported elsewhere in the literature, possibly due to the effect of using an oto-endoscope. STUDY DESIGN: Retrospective case review, with data entered prospectively for operations performed by a single surgeon. SETTING: Tertiary referral hospital. @entity1 : Between January 1998 and December 2004 inclusive, 66 @entity1 underwent 68 primary procedures, with data available for all 'second looks'. INTERVENTIONS: Diagnostic and therapeutic operations for @entity3540 were performed. MAIN OUTCOME MEASURES: All @entity1 in this study attended follow up and underwent a second look operation, during which the rate of residual and recurrent @entity3540 was determined. An oto-endoscope was used at all primary and subsequent surgery. RESULTS: The mean interval between the first and second combined approach tympanoplasty procedures was 16 months, and that between the second and third such procedures was 19 months (10 @entity1 ). One @entity1 underwent a fourth combined approach tympanoplasty procedure, 17 months after a third such procedure. The rate of @entity3540 at second combined approach tympanoplasty was 20.6 per cent (14/68); this was judged to be residual in 10 ears (14.7 per cent) and to be recurrent, with the redevelopment of retraction pockets, in four ears (5.9 per cent). The rate of @entity3540 at third combined approach tympanoplasty was 20 per cent (two of 10); of these two, one @entity1 had a small pearl in the middle ear removed with the aid of a @entity17835 laser. There was no disease present in one @entity1 at a fourth combined approach tympanoplasty. Only four @entity1 required a modified radical mastoidectomy. CONCLUSION: @entity3540 remains a disease with significant morbidity. Endoscope-assisted surgery may decrease the morbidity of second look surgery and may improve the clearance of disease in appropriately selected @entity1 .

title: Combined approach tympanoplasty for XXXX : impact of middle-ear endoscopy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity3540 :: ('MESH:D002781', 'Disease') :: ['cholesteatoma', 'Cholesteatoma']

entities_list: @entity17835 :: ('MESH:C064806', 'Chemical') :: ['potassium titanyl phosphate']

answer: @entity3540 :: (MESH:D002781,Disease) :: ['cholesteatoma']


abstract: STUDY DESIGN: We investigated the effects of standardized facilitation on stability in amplitude of the motor-evoked potentials from the deltoid muscle after magnetic stimulation over the scalp in normal study @entity1 . OBJECTIVES: To test the potential of this technique in evaluating @entity425 and recovery after @entity2244 . SUMMARY OF BACKGROUND DATA: Most previous motor-evoked potential studies have emphasized the value of the latency rather than amplitude, probably because the amplitude varies much more than the latency, even in the same individual. METHODS: Twenty right-handed healthy @entity1 underwent deltoid motor-evoked potential studies on three successive occasions at intervals of >2 weeks. A digital readout of the shoulder abduction force allowed the study @entity1 to adjust voluntary contraction to 20% of the maximal force at the moment of stimulation. The deltoid motor-evoked potentials were compared with the M responses recorded from the relaxed deltoid after electrical stimulation of the brachial plexus. RESULTS: Despite considerable individual variability in the amplitude of deltoid motor-evoked potentials, a standardized facilitation yielded a relatively small variation of amplitude between sessions in the same individual, showing an intersession variability index of 9.1 +/- 7.9%. The side-to-side amplitude ratio, averaging 82 +/- 12%, also provides a more reliable measure in evaluating unilateral @entity425 than the absolute value. The measures on the left showed significantly higher amplitude than on the right for the deltoid motor-evoked potentials but not for the M responses. CONCLUSIONS: The changes of the motor-evoked potential amplitude exceeding 25% between sessions and side-to-side amplitude ratios <60% can be outside the normal limits. The asymmetry of deltoid motor-evoked potentials in favor of the nondominant side is of physiologic interest.

title: The motor-evoked potentials elicited from the deltoid muscle by transcranial magnetic stimulation with a standardized facilitation: the potential diagnostic utility for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'participant', 'men']

entities_list: @entity2244 :: ('MESH:C537005', 'Disease') :: ['C5 radiculopathy']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['deltoid weakness']

answer: @entity2244 :: (MESH:C537005,Disease) :: ['C5 radiculopathy']


abstract: Stimulation of central tachykinin receptors contributes to neuroendocrine functions of the hypothalamo-neurohypophyseal system. However, the specific role of each @entity4756 receptor subtype has not been completely characterized. Specifically, while neurokinin 3 (NK3) receptor stimulation increases systemic vasopressin, the effects on @entity398 (OT) are not known. Therefore, the present studies investigated the effect of central @entity28014 stimulation with senktide on release of systemic and central OT. Furthermore, since central NK3 receptors activate noradrenergic systems, which contribute to OT release, the effects of alpha-adrenergic receptor blockade on senktide-induced changes in OT release were evaluated. Female @entity35 were implanted with a cannula in the third cerebral ventricle, and changes in plasma OT concentration determined before and following central administration of senktide in vehicle-treated @entity35 , and animals following central administration of the alpha-adrenergic antagonist @entity5521 . Other @entity35 were implanted with microdialysis probes adjacent to the paraventricular nucleus (PVN), and dialysate and plasma OT concentrations were determined before and during administration of senktide through the dialysis probe. Central senktide increased systemic OT release, which was prevented by pretreatment with @entity5521 . Furthermore, there was no detectable change in extracellular OT concentration in the PVN during dialysis administration of senktide. These data demonstrate that activation of central NK3 receptors stimulates systemic release of OT by activation of central noradrenergic systems, apparently without increasing intranuclear OT release in the PVN.

title: Central neurokinin 3 receptors increase systemic XXXX release: interaction with norepinephrine.

entities_list: @entity398 :: ('MESH:D010121', 'Chemical') :: ['oxytocin']

entities_list: @entity5521 :: ('MESH:D010646', 'Chemical') :: ['phentolamine']

entities_list: @entity4756 :: ('MESH:D015320', 'Chemical') :: ['tachykinin']

answer: @entity398 :: (MESH:D010121,Chemical) :: ['oxytocin']


abstract: OBJECTIVE: To investigate the risk of @entity600 among liveborn singletons to primiparas who conceived with assisted reproductive technology (ART) using four mutually exclusive categories of @entity249 ( @entity9814 only, @entity4810 only, female and @entity4810 , and @entity249 ) and to examine @entity600 risk along the gestational age continuum. DESIGN: Retrospective cohort study. SETTING: Not applicable. @entity1 (S): Singletons born to primiparas who conceived with or without ART. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Preterm (<37 weeks' gestation) and preterm/early term birth <39 weeks' gestation). RESULT(S): For the @entity4810 only, @entity9814 only, combined male and @entity9814 , and @entity249 groups, ART-conceived singletons were significantly more likely than non-ART singletons to be born preterm: adjusted odds ratio (aOR) 1.24 (95% CI, 1.13, 1.37), aOR 1.60 (95% CI, 1.50, 1.70), aOR 1.49 (95% CI, 1.35, 1.64), and aOR 1.26 (1.12, 1.43) respectively. Among @entity1 whose mothers were diagnosed with @entity249 , the odds of @entity600 were highest between 28-30 weeks [ @entity9814 only, aOR 1.95 (95% CI, 1.59, 2.39); male and @entity9814 : 2.21 (95% CI, 1.62, 3.00)] compared with @entity1 in the general population. Within the ART population, singletons of couples with @entity9814 only were more likely to be born preterm than singletons born to couples with other @entity249 diagnoses. CONCLUSION(S): Among singleton births to primiparas, those conceived with ART had an increased risk for @entity600 , even when only the male partner had been diagnosed with @entity249 . The risk of @entity600 for ART-conceived @entity1 whose mothers were diagnosed with @entity249 included the earliest deliveries.

title: Assisted reproductive technology and the risk of XXXX among primiparas.

entities_list: @entity1 :: ('9606', 'Species') :: ['infants', 'PATIENT']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility', 'unexplained infertility']

entities_list: @entity4810 :: ('MESH:D007248', 'Disease') :: ['male infertility']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['preterm birth']

entities_list: @entity9814 :: ('MESH:D007247', 'Disease') :: ['female infertility']

answer: @entity600 :: (MESH:D000014,Disease) :: ['preterm birth']


abstract: OBJECTIVES: To analyze the predictive power of Ki67 area% (Ki67), mitotic activity index (MAI), @entity876 area% ( @entity876 ), and the mean area of the 10 largest nuclei (MNA10) for progression of stage in 195 primary consecutive @entity16064 urothelial cell @entity189 of the urinary bladder. METHODS: Ki67- and @entity876 -positive versus negative nuclei, MAI, and MNA10 using motorized systematic random sampling morphometry were determined. Kaplan-Meier curves and multivariate survival analysis (Cox model) were used to assess the prognostic value of the quantitative and classic clinicopathologic risk factors (age, sex, stage, grade, @entity189 in situ, multicentricity). RESULTS: Thirteen (6.7%) of the 195 @entity1 had progression (0 [0%] of 36 low-risk, 1 [1.1%] of 85 intermediate-risk, and 12 [16.2%] of 74 high-risk @entity1 ). In univariate analysis (all variables), the strongest predictors with the highest hazard ratios were Ki67 (threshold 25.0%), MAI (threshold 30), and MNA10 (threshold 170 microm2). In multivariate analysis, the strongest independent combinations for progression--MNA10 (170 microm2) plus MAI (threshold 30) and MNA10 (threshold 170 microm2) plus Ki67 (threshold 25.0%)--overshadowed all other features. @entity876 was weaker but, combined with Ki67, still predicted progression fairly well. In the total group, the sensitivity, specificity, and positive and negative predictive values of MNA10-MAI and MNA10-Ki67 at the thresholds mentioned were 100%, 89%, 38%, and 100%, respectively. These feature combinations were also strongest prognostically in the high-risk treatment group. CONCLUSIONS: The combined biomarkers MNA10-MAI or MNA10-Ki67 are accurate, well reproducible, and easy to assess progression predictors in all @entity1 with @entity16064 urothelial cell @entity189 , as well as in high-risk (bacille Calmette-Gu  rin-treated) @entity1 .

title: Prognostic value of proliferative activity and nuclear morphometry for progression in @entity16064 urothelial cell XXXX of the urinary bladder.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'carcinoma']

answer: @entity189 :: (MESH:D002277,Disease) :: ['carcinomas']


abstract: OBJECTIVE: To clarify a potential therapeutic role of coenzyme Q(10) ( @entity7447 ) in infertile @entity1 with idiopathic @entity19474 . DESIGN: Open, uncontrolled pilot study. @entity1 (S): Infertile @entity1 with idiopathic @entity19474 . INTERVENTION(S): @entity7447 was administered orally; semen samples were collected at baseline and after 6 months of therapy. MAIN OUTCOME MEASURE (S): Semen kinetic parameters, including computer-assisted sperm data and CoQ(10) and @entity2434 levels. RESULT(S): @entity7447 levels increased significantly in seminal plasma and in sperm cells after treatment. @entity2434 levels also increased. A significant increase was also found in sperm cell motility as confirmed by computer-assisted analysis. A positive @entity734 (using the Cramer's index of association) was evident among the relative variations, baseline and after treatment, of seminal plasma or intracellular @entity7447 content and computer-determined kinetic parameters. CONCLUSION(S): The exogenous administration of CoQ(10) may play a positive role in the treatment of @entity19474 . This is probably the result of its role in mitochondrial bioenergetics and its antioxidant properties.

title: Coenzyme Q(10) supplementation in infertile XXXX with idiopathic @entity19474 : an open, uncontrolled pilot study.

entities_list: @entity19474 :: ('MESH:D053627', 'Disease') :: ['asthenozoospermia']

entities_list: @entity2434 :: ('MESH:D010713', 'Chemical') :: ['Phosphatidylcholine', 'phosphatidylcholine']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence']

answer: @entity1 :: (9606,Species) :: ['men']


abstract: INTRODUCTION: The aim is to analyze the functional outcomes of @entity1 of @entity2967 ( @entity2967 ) of distal radius treated with ulnar translocation and wrist arthrodesis. METHODS: Study included 25 @entity1 of aggressive @entity2967 of distal radius, resected and reconstructed using ulnar translocation and wrist arthrodesis. The ulna-carpal radius fixation was performed with plate and screws. The @entity1 were followed to bony union and minimum follow-up was 1 year. RESULT: Twenty-two @entity1 were of Campanacci grade 3 and three @entity1 were of Campanacci grade2. The mean follow-up was of 23 months (12-36). All @entity1 had an excellent range of pronation and supination. The mean Musculoskeletal Tumor Society score was 24 (range 22-28). Grip strength of affected hand compared to the contra lateral hand was found good in 17 cases and average in 7 cases. The mean bone union time at ulna to radius junction was at 6.5 (5-8) months and ulna to carpal junction at 4.5 (4-6) months. The complications were @entity281 (one case), recurrence (one case) and failure of union (one case), and ulna graft fracture with implant failure in (two cases). CONCLUSION: Reconstruction of distal end of radius using ulnar translocation and wrist arthrodesis provides excellent functional outcomes with preservation of rotational movement of forearm and hand function. Reconstruction of the distal radius by ulnar translocation without complete detachment from surrounding soft tissues functions like vascularized graft without use of microvascular techniques.

title: XXXX of distal radius treated with ulnar translocation and wrist arthrodesis.

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['surgical site infection']

entities_list: @entity2967 :: ('MESH:D005870', 'Disease') :: ['giant cell tumor', 'GCT']

answer: @entity2967 :: (MESH:D005870,Disease) :: ['Giant cell tumor']


abstract: @entity157 ( @entity157 ) is a major health problem. Mortality owing to @entity96 has increased in the past 20 years, with recent studies reporting an incidence of 780,000 cases/year. Most @entity1 with @entity157 are still diagnosed at intermediate or advanced disease stages, where curative approaches are often not feasible. Among the treatment options available, the molecular targeted agent @entity2857 is able to significantly increase overall survival in these @entity1 . Afterwards, up to 7 randomized phase III clinical trials investigating other molecular therapies in the first-line and second-line settings have failed to improve survival. Potential reasons for this include intertumor heterogeneity, issues with trial design and a lack of predictive biomarkers of response. Advance in our knowledge of the @entity1 genome has provided a comprehensive picture of commonly mutated genes in @entity1 with @entity157 including mutations in the @entity2215 promoter, @entity3546 , @entity876 and @entity10161 along with other amplifications ( @entity30361 , @entity7 ) or homozygous deletions ( @entity986 ) as the most frequent alterations. This knowledge points toward specific drivers as candidate for druggable therapies. Thus, progressive implementation of proof-of-concept and enrichment might improve results in clinical trials testing of molecular targeted agents. Ultimately, these studies are aimed at long-term to improve current standards of care and influenced clinical decision-making and practice guidelines.

title: New molecular therapies for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'human']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver cancer']

entities_list: @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Hepatocellular carcinoma', 'hepatocellular carcinoma']

answer: @entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']


abstract: Background/Aims: @entity3478 ( @entity3478 ) is one of the most common @entity158 in @entity1 with advanced @entity5 . Because of treatment-associated side effects, more than half of @entity5 @entity1 are reported to have inadequate and undermanaged @entity158 control. New mechanism-based therapies must be developed to reduce @entity5 . @entity1089 is a commonly used atypical antipsychotic drug. We report a study of the potential analgesic effects of @entity1089 in a @entity19 model of @entity3478 and examine the mechanism of @entity158 by analyzing the expression of various nociceptors. Methods: Fifteen male C3H/HeN @entity19 were arbitrarily divided into five groups: control and, @entity3478 with no treatment, @entity1089 treatment, opioid treatment, and @entity2493 treatment. The @entity19 were tested for mechanical @entity1931 by determining the nociceptive hind paw withdrawal pressure threshold. Tissues from tibia were removed and subjected to quantitative and qualitative evaluations of @entity4412 ( @entity4412 ), @entity18540 , @entity21296 ( @entity21296 ), @entity10871 , and @entity10872 expression. Results: Paw withdrawal pressure threshold was improved in the @entity1089 treatment group compared with the @entity3478 group. Expression of @entity4412 , @entity18540 , @entity21296 , @entity10871 , and @entity10872 in the @entity3478 with @entity1089 treatment group was significantly lower than that in the @entity3478 group. Conclusions: Our results suggest an analgesic effect of @entity1089 in the @entity3478 animal model and implicate TRPV and ASICs as potential targets for @entity5 management.

title: Analgesic effect of XXXX in a @entity19 model of @entity5 -induced @entity158 .

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesia']

entities_list: @entity3478 :: ('MESH:D001859', 'Disease') :: ['CIBP', 'Cancer-induced bone pain']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms', 'cancer', 'cancer pain']

entities_list: @entity4412 :: ('193034(Tax:10090)', 'Gene') :: ['transient receptor potential vanilloid 1', 'TRPV1']

entities_list: @entity2493 :: ('MESH:D008550', 'Chemical') :: ['melatonin']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['bone pain', 'pain', 'pains']

entities_list: @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine', 'Quetiapine']

answer: @entity1089 :: (MESH:C069541,Chemical) :: ['quetiapine']


abstract: The lack of evolutionary established mechanisms linking genes to age-related traits makes the problem of genetic susceptibility to health span inherently complex. One complicating factor is genetic trade-off. Here we focused on long-living @entity1 of the Long Life Family Study (LLFS), their offspring, and spouses to: (1) Elucidate whether trade-offs in the effect of the @entity2204 e4 allele documented in the Framingham Heart Study (FHS) are a more general phenomenon, and (2) explore potential mechanisms generating age- and gender-specific trade-offs in the effect of the e4 allele on @entity5 , @entity299 , and @entity179 assessed retrospectively in the LLFS populations. The e4 allele can diminish risks of @entity5 and @entity299 and confer risks of @entity299 in a sex-, age-, and LLFS-population-specific manner. A protective effect against @entity5 is seen in older long-living @entity1 and, potentially, their sons (>75 years, relative risk [RR]>75=0.48, p=0.086), which resembles our findings in the FHS. The protective effect against @entity299 is limited to long-living older @entity1 (RR>76=0.50, p=0.016), as well. A detrimental effect against @entity299 is characteristic for a normal LLFS population of male spouses and is specific for @entity583 (RR=3.07, p=2.1*10(-3)). These trade-offs are likely associated with two inherently different mechanisms, including disease-specific (detrimental; characteristic for a normal male population) and systemic, aging-related (protective; characteristic for older long-living @entity1 ) mechanisms. The e4 allele confers risks of @entity16 in @entity1 and @entity1 (RR=1.98, p=0.046). The results highlight the complex role of the e4 allele in genetic susceptibility to health span.

title: Trade-offs in the effects of the XXXX polymorphism on risks of @entity299 , @entity5 , and @entity179 : insights on mechanisms from the Long Life Family Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'men']

entities_list: @entity2204 :: ('348', 'Gene') :: ['apolipoprotein E']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorders']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disorders']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['diseases of the heart']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity2204 :: (348,Gene) :: ['apolipoprotein E']


abstract: BACKGROUND: It is possible that oxidative stress causes several @entity989 . However, the natural biogenic role of antioxidants in the retina is not clear. PURPOSE: This study investigates the change in concentration of @entity270 (VE), @entity9050 and @entity2041 ( @entity2197 ) in the retina following vitreous injection of 600 mug 18:2 @entity43059 (LHP) in male @entity95 . METHOD: LHP was injected above the retinal surface. The animals were sacrificed and the eyes enucleated before LHP injection, 1, 3, 6, 12, 24 h and 4 and 7 days after LHP injection. Retinas were removed, VE and @entity9050 measured by HPLC, and @entity2197 determined by a fluorometric method. RESULTS: The concentration of VE in the retina decreased from pretreatment levels of 154.6 +/- 29.7 nmol/g wet weight (n = 7) and was lowest at 6 h (61.1 +/- 18.1 nmol/g wet weight, n = 4, p < 0.05), then increased gradually, returning slowly to pre-LHP levels by 7 days. The concentration of @entity9050 in control retinas decreased at 6 h from pretreatment levels of 7.33 +/- 0.93 micromol/g wet weight (n = 7) to 2.74 +/- 0.16 micromol/g wet weight (n = 4, p < 0.05) and returned to pretreatment levels rapidly by 24 h after injection. The concentration of @entity2197 in retinas decreased from baseline levels of 109.53 +/- 8.19 microg/g wet weight (n = 9), was lowest at 12 h (72.40 +/- 11.17 microg/g wet weight, n = 5, p < 0.05) and returned to pretreatment levels by 7 days. CONCLUSION: The results suggest that intravitreous LHP injection is a contributor to oxidative stress in the @entity95 retina by causing a reduction in antioxidant capacity.

title: Effect of lipid-hydroperoxide-induced oxidative stress on @entity270 , @entity9050 and @entity2041 in the XXXX retina.

entities_list: @entity270 :: ('MESH:D014810', 'Chemical') :: ['vitamin E']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbit', 'New Zealand rabbits']

entities_list: @entity43059 :: ('MESH:C008285', 'Chemical') :: ['linoleic acid hydroperoxide']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinal diseases']

entities_list: @entity9050 :: ('CHEBI:38290', 'Chemical') :: ['ascorbate']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: OBJECTIVE: To evaluate the recurrence of lymphatic metastases in @entity1 with @entity1544 treated with supraomohyoid neck dissection with and without postoperative radiotherapy. DESIGN: A nonrandomized retrospective study. SETTING: Department of Otolaryngology and Head and Neck, State University of Campinas, S  o Paulo, Brazil, a tertiary referral center. @entity1 : Thirty-two @entity1 with @entity1544 without previous treatment and a minimum follow-up period of 2 years were studied. There were 36 supraomohyoid neck dissections, of which 31 were elective (clinically negative nodes) and 5 therapeutic (clinically positive nodes). INTERVENTION: Resection of the primary @entity5 and supraomohyoid neck dissection, with or without postoperative radiotherapy. MAIN OUTCOME MEASURES: Evaluation of @entity135 recurrence according to clinical and histopathological findings in the neck and use of postoperative radiotherapy. RESULTS: The overall recurrence rate was 6% (2 @entity1 ). Recurrences were seen in 1 clinically negative neck (3%) and 1 clinically positive neck (20%). The presence of clinically or histopathologically positive nodes, number of positive nodes, and use of adjuvant radiotherapy did not influence the rate of @entity135 recurrence with a statistically significant difference. CONCLUSIONS: @entity135 recurrence in procedures with clinically positive nodes was 6.3 times greater than in those with clinically negative nodes. There was no difference in regional recurrence of histopathologically positive node necks with or without the addition of postoperative radiotherapy. @entity135 recurrence was not statistically influenced by clinically and histopathologically positive nodes, multiple positive nodes, and use of postoperative radiotherapy.

title: Regional XXXX recurrence after supraomohyoid neck dissection.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1544 :: ('MESH:D018307', 'Disease') :: ['squamous cell carcinoma of the oral cavity']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['Neck tumor', 'neck tumor']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: The effect of physical activity on @entity3140 was examined in this population-based case control study with 321 age- and gender-matched pairs. Sports participation increased @entity174 risk in @entity1 and decreased risk in @entity1 . Television viewing had a deleterious dose response association with wrist and @entity174 while light physical activity was protective. INTRODUCTION: The aim of this population-based case control study was to examine the association between television, computer, and video viewing; types and levels of physical activity; and @entity3140 in @entity1 9-16 years of age. MATERIALS AND METHODS: A total of 321 @entity174 cases and 321 randomly selected individually matched controls were studied. Television, computer, and video viewing and types and levels of physical activity were determined by interview-administered questionnaire. Bone strength was assessed by DXA and metacarpal morphometry. RESULTS: In general, sports participation increased total @entity3140 risk in @entity1 and decreased risk in @entity1 . Gender-specific risk estimates were significantly different for total, contact, noncontact, and high-risk sports participation as well as four individual sports (soccer, cricket, surfing, and swimming). In multivariate analysis, time spent television, computer, and video viewing in both sexes was positively associated with wrist and @entity174 risk ( @entity13562 /category, 95% CI: 1.1-2.2), whereas days involved in light physical activity participation decreased @entity174 risk (OR 0.8/category, 95% CI: 0.7-1.0). Sports participation increased hand (OR 1.5/sport, 95% CI: 1.1-2.0) and upper arm (OR 29.8/sport, 95% CI: 1.7-535) @entity174 risk in @entity1 only and decreased wrist and @entity174 risk in @entity1 only (OR 0.5/sport, 95% CI: 0.3-0.9). Adjustment for bone density and metacarpal morphometry did not alter these associations. CONCLUSION: There is gender discordance with regard to sports participation and @entity174 risk in @entity1 , which may reflect different approaches to sport. Importantly, television, computer, and video viewing has a dose-dependent association with wrist and @entity174 , whereas light physical activity is protective. The mechanism is unclear but may involve bone-independent factors, or less likely, changes in bone quality not detected by DXA or metacarpal morphometry.

title: Television, computer, and video viewing; physical activity; and @entity3140 risk in XXXX : a population-based case control study.

entities_list: @entity3140 :: ('MESH:D038062', 'Disease') :: ['upper limb fracture', 'upper limb fractures']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'girls', 'boys']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['forearm fracture', 'forearm fractures', 'fracture']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: In animal models of @entity583 , n-3 @entity1474 ( @entity5204 ) administered before coronary occlusion have been suggested to prevent induction of @entity943 and limit @entity1188 size. However, the relation between the serum levels of n-3 @entity5204 and @entity63 /reperfusion (I/R) injury remains unclear. METHODS: 211 @entity1 with ST-segment elevation @entity583 received emergency percutaneous coronary intervention (PCI) within 6h from the onset. The @entity1 were divided into two groups according to the sum of serum @entity7784 ( @entity8393 ) levels and @entity4600 ( @entity4601 ) levels before PCI: group L (n=106), @entity8393 + @entity4601 <155 g/ml and group H (n=105), @entity8393 + @entity4601 >= 155 g/ml. The Selvester QRS-scoring system was used to estimate the serial change in @entity1188 size. RESULTS: Time to reperfusion was similar between the 2 groups. The QRS score before PCI was higher in group L than in group H (2.42  2.00 vs 1.85  2.01, p=0.015). The proportion of @entity1 with I/R injury immediately after reperfusion, defined as reperfusion @entity943 (25% vs 11%, p=0.006) and ST-segment re-elevation (44% vs 22%, p<0.001), was also higher in group L than in group H, followed by a greater increment in the QRS score during PCI (3.51  2.51 vs 2.54  1.91, p=0.006) and higher peak levels of @entity1011 phosphokinase (3552  241U/L vs 2660  242U/L, p<0.01). On multivariate analysis, serum level of @entity8393 + @entity4601 was an independent predictor of @entity5721 (odds ratio 0.985, p=0.032). CONCLUSION: Serum level of n-3 @entity5204 before PCI may be a predictor of I/R injury and the resultant extent of @entity296 . These findings suggest a protective effect of serum n-3 @entity5204 on ischemic myocardium.

title: Impact of n-3 @entity1474 in predicting @entity63 / @entity5721 and progression of XXXX after reperfusion in @entity1 with ST-segment elevation @entity583 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity7784 :: ('MESH:D015118', 'Chemical') :: ['eicosapentaenoic acid']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial damage']

entities_list: @entity5721 :: ('MESH:D015427', 'Disease') :: ['reperfusion injury']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity4600 :: ('CHEBI:28125', 'Chemical') :: ['docosahexaenoic acid']

entities_list: @entity1474 :: ('MESH:D005231', 'Chemical') :: ['polyunsaturated fatty acids']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmia', 'ventricular arrhythmias']

answer: @entity296 :: (MESH:D009202,Disease) :: ['myocardial damage']


abstract: AIMS: To carry out a systematic review to consolidate current knowledge on the potential association between @entity10410 ( @entity10410 ) and @entity387 ( @entity387 ). METHODS: For this systematic review, articles were retained only if they reported studies using full ambulatory polysomnography as "the gold standard" reference test to determine @entity387 and the international diagnostic criteria proposed by the American Association of Sleep Medicine to determine @entity10410 . Detailed individual search strategies from MEDLINE, PubMed, Embase, the Cochrane Library, and LILACS databases were developed. The references cited in the selected articles were also checked, and a partial literature search was undertaken. The selection was completed independently by two reviewers in two phases. The methodology of selected studies was evaluated using the seven-item quality-assessment tool for experimental @entity8599 studies. RESULTS: During the initial search, 333 different citations were identified across the six electronic databases. After a comprehensive evaluation of the abstracts, and the full papers when considered necessary, only one study was finally selected for the qualitative/quantitative synthesis. This study did not support the putative association between @entity10410 and @entity387 , since @entity10410 was not observed during or in temporal conjunction with snoring or apneic events in any of the evaluated @entity1 . In addition, masseter activity was not observed during @entity2749 . CONCLUSION: There is not sufficient scientific evidence either to confirm or discredit the association between @entity10410 and @entity387 .

title: Sleep @entity8599 and XXXX : a systematic review.

entities_list: @entity2749 :: ('MESH:C580065', 'Disease') :: ['apneic episodes']

entities_list: @entity387 :: ('MESH:D012891', 'Disease') :: ['sleep-disordered breathing', 'SDB']

entities_list: @entity10410 :: ('MESH:D020186', 'Disease') :: ['sleep bruxism', 'SB']

answer: @entity387 :: (MESH:D012891,Disease) :: ['sleep-disordered breathing']


abstract: PURPOSE: The medical cost of @entity6 in the United States in 1997 was at least  98 billion. This study illustrates the behavioral change and medical-care utilization impact that occurs in a community-based setting of a @entity6 -management program that is applied to program @entity1 in a health insurance plan's health maintenance organization and preferred provider organization. DESIGN: A historical control comparison of @entity6 -management @entity1 . METHODOLOGY: One hundred twenty-seven identified @entity6 @entity1 are followed from baseline through 1 year. Differences in behavior are compared at program intake and at a 6-month reassessment. Differences in medical-service utilization are compared in the baseline year and the year subsequent to program enrollment. Poisson multivariate-regression models are estimated for counts of inpatient, emergency department, physician evaluation and management, and facility visits, while also controlling for potential confounders. PRINCIPAL FINDINGS: Behaviors improved between program intake and the 6-month reassessment. From @entity1 reports, the number of @entity1 having a hemoglobin A1c test increased by 44.9 percent (p < .001), and there was a 53.2-percent decrease in symptoms of @entity4854 (p = .002). From medical claims after program enrollment, a drop occurred during the program year in every dimension of medical-service utilization. Regression results show that in- @entity1 admissions decreased by 391 (p < .001) per 1,000 for each group, while controlling for age, length of membership, and the number of comorbid claims for @entity712 . In the analysis of costs that were pre- and post-enrollment, which included disease-management program costs, a 4.34:1 return on investment was calculated. CONCLUSION: The @entity6 program provides @entity1 with comprehensive information and counseling relative to practicing self-management of @entity6 through a number of integrated program components. This study strongly suggests that the implementation of such a program is associated with positive behavioral change and, thus, with substantial reduction in medical-service utilization. In addition, the intervention resulted in a net decrease in direct medical costs.

title: XXXX management in a community-based setting.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'diabetes disease']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes disease']


abstract: PURPOSE: To describe the course, management, and prognosis of massive spontaneous @entity548 . METHODS: The presenting visual acuity, ocular findings, duration to surgical intervention, and outcomes of five @entity1 were retrospectively reviewed. RESULTS: Five eyes from four @entity1 (median age, 80 years; range, 66-85 years) were studied. The @entity1 were observed from 4 to 72 months (median, 33 months). Three @entity1 were on anticoagulation therapy with @entity1229 ; one @entity1 had bilateral involvement with no history of anticoagulation therapy. Three @entity1 were @entity101 , and three of the four had been diagnosed with age-related @entity1020 . Four eyes underwent choroidal drainage procedures, and one was observed. In all @entity1 whose choroids were drained, the final vision was no light perception. CONCLUSIONS: Massive spontaneous @entity548 may be associated with @entity101 , systemic anticoagulation, advanced age, and age-related @entity1020 . Final visual acuities are generally poor.

title: Massive spontaneous XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['choroidal hemorrhage']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']

answer: @entity548 :: (MESH:D006470,Disease) :: ['choroidal hemorrhage']


abstract: AIM: To verify the expressing efficiency and angiogenesis effect after administration of expression vector encoding for vascular endothelial growth factor D in normal and @entity63 @entity35 liver. METHODS: Ten female S-D @entity35 were administrated with liver tissue dot injection of naked PCHO/ @entity9205 , 50 microg/dot, three dots for each. The same amount of physiological saline was used as control in the neighboring lobe. Fourteen S-D @entity35 , using inflow occlusion of left lateral lobe, were divided into two groups, seven @entity35 in each group. One was @entity63 plasmid group, which received naked plasmid @entity67025 / @entity9205 injection of 150 microg. The other received the equal amount of natural saline injection and designed as control. The expressions of @entity9205 in mRNA and protein levels were identified by in situ hybridization and immunohistochemistry, respectively. Endothelial cells were labeled by the factor VIII immunohistochemistrically. The average number of peri-sinusoidal capillaries of each group was calculated and compared statistically 8 days after injection. RESULTS: A large amount of @entity9205 in mRNA level was found in both normal and @entity63 plasmid groups and but none in their corresponding control groups. The protein of @entity7 was also highly expressed in both normal and @entity63 plasmid groups than in the controls. The mean number of capillaries under microscopy (X200) of the plasmid group and control was 10.2+/-2.78 vs 7.1+/-2.02 (P<0.05), and those of @entity63 plasmid group and @entity63 control were 7.43+/-1.72 vs 4.71+/-1.11 with statistical difference (P<0.05). CONCLUSION: The naked PCHO/ @entity9205 dot injection to normal, @entity63 @entity35 liver can produce comparatively high expression of @entity7 in both protein and mRNA levels, and prominently increase the number of new capillaries around hepatic sinuses. Therefore, it could be another ideal choice for the treatment of @entity409 .

title: Angiogenesis effect on XXXX liver after administration of expression vector encoding vascular endothelial growth factor D.

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['ischemic liver diseases']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: @entity4409 ( @entity4409 ) interventions have been shown to assist in coping and improve @entity1 responses to symptoms. Specifically, the presence of an animal has been found to lower @entity148 and motivate participation in therapy. We aimed to explore the acceptability of and experience of @entity4409 during individual @entity0 counseling sessions. METHODS: @entity1 undertaking counseling with a therapy @entity235 present were invited to participate in the study. @entity1 were individually interviewed and asked to reflect on their experiences of @entity4409 . Data generation and analysis were concurrent. Transcripts were analyzed thematically using a process of constant comparison. RESULTS: Our sample included 8 female @entity1 , 39 to 61 years old, at an average of 3 years post- @entity0 diagnosis. The majority of @entity1 reported a positive experience with @entity4409 . Themes that emerged around their counseling experience included benefits in the process of initiating counseling and benefits for greater engagement and personal disclosure. CONCLUSIONS: Incorporating @entity4409 into the delivery of counseling for @entity0 @entity1 appears to be feasible and acceptable at a @entity1 level. From a clinical perspective, @entity4409 promoted increased communication with health professionals. This is of clinical importance as a means to improve participation and engagement in therapy-important elements in therapeutic outcomes. However, further evaluation of the impact of @entity4409 on specific @entity1 outcomes and @entity5845 is required.

title: Animal-Assisted Therapy and Counseling Support for @entity1 With @entity0 : An Exploration of XXXX 's Perceptions.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity4409 :: ('MESH:D000820', 'Disease') :: ['Animal-assisted therapy', 'AAT']

entities_list: @entity5845 :: ('MESH:D009767', 'Disease') :: ['psychological morbidity']

answer: @entity1 :: (9606,Species) :: ['Patient']


abstract: INTRODUCTION: A new, highly filled primer is currently marketed as a @entity1388 delivery system effective in reducing @entity62 in orthodontic @entity1 . However, no studies in the literature support this claim. The purpose of this in-vivo study was to investigate the retention and the efficacy of this primer in reducing the formation of @entity62 . METHODS: In each @entity1 for whom premolar extractions were planned (n = 22), 1 premolar was randomly chosen as the experimental tooth for the application of the @entity1388 delivery system (Opal Seal; Ultradent Products, South Jordan, Utah), and the contralateral tooth was assigned as the control to receive the standard treatment (Transbond XT; 3M Unitek, Monrovia, @entity2948 ). After the bonding procedures, separators were placed around the premolar brackets to encourage plaque retention over 8 weeks. After the extractions, the tooth surfaces were evaluated visually and with microhardness techniques for @entity3760 . Primer retention was also investigated. RESULTS: There were no statistically significant differences in the numbers of @entity62 between the 2 groups. The primer retention was calculated as 50%. CONCLUSIONS: The results indicated no significant difference between the efficacies of the @entity1388 -releasing primer and the control primer in reducing @entity3760 over the duration of the study.

title: Efficacy of a XXXX -releasing orthodontic primer in reducing @entity3760 around brackets: an in-vivo study.

entities_list: @entity3760 :: ('MESH:D017001', 'Disease') :: ['demineralization']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['white spot lesions']

entities_list: @entity1388 :: ('MESH:D005459', 'Chemical') :: ['fluoride']

answer: @entity1388 :: (MESH:D005459,Chemical) :: ['fluoride']


abstract: OBJECTIVE: To investigate the mechanisms of @entity1369 stimulating hepatic stellate cells(HSCs) contraction via @entity141 -independent pathways. METHODS: HSC-T6 cell line was pre-disposed with Aldo 10mumol/L. The cell contraction was detected by @entity1346 -rubber-membrane cultivation directly. The concentration variation of intracellular free @entity460 in @entity35 HSC was observed by laser confocal microscopy. Besides, HSC-T6 cell line was under pre-disposal treatment with the blocking agents of Aldo receptor -antisterone, protein kinase C (PKC) special blocking agent-Stauro, Rho kinase blocking agent-Y27632 and @entity31490 special blocking agent- @entity19102 respectively prior to stimulation with @entity1369 . RT-PCR was used to detect the expression of @entity13291 , RhoAGTP and RhoGEF in @entity141 - independent pathways mediated by Rho-kinase. RESULTS: Aldo could induce HSCs contraction. The concentration of intracellular free @entity460 in @entity35 HSCs had no change after pre-disposal treatment with Aldo. The mRNA expressions of @entity13291 , RhoAGTP and RhoGEF increased significantly after treatment with Aldo (0.770+/-0.049, 0.960+/-0.096, 0.180+/-0.006, P is less than 0.01).When inhibited with antisterone, the mRNA expressions of the three elements were (0.440+/-0.166, 0.370+/-0.180 and 0.050+/-0.001, P is less than 0.01), lower than that of Aldo group, but higher in @entity19102 +Stauro + Aldo groups (0.940+/-0.066, 1.330+/-0.192 and 0.160+/-0.007, P is less than 0.05) as compared to the control group (0.140+/-0.023, 0.540+/-0.111 and 0.110+/-0.012). In the Y27632 + @entity19102 + Stauro+Aldo group, the mRNA expression of RhoGEF (0.290+/-0.004, P is less than 0.01)was higher than that of the @entity19102 + Stauro + Aldo group (0.160+/-0.007). CONCLUSION: Aldo could induce HSCs contraction via @entity141 -independent pathways and Rho-Rock pathway involved in the process.

title: [ @entity1369 stimulates hepatic stellate cells contraction via XXXX -independent pathways].

entities_list: @entity1369 :: ('MESH:D000450', 'Chemical') :: ['Aldosterone', 'aldosterone']

entities_list: @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity141 :: (CHEBI:29108,Chemical) :: ['Ca2+']


abstract: The craniocervical junction (CCJ) functions within a complicated regional anatomy necessary to protect and support vital neurovascular structures. In select instances, vascular pathology can be attributed to this complicated interplay of motion and structure found within this narrow space. The authors report 3 cases of complex vascular pathology related to motion at the CCJ and detail the management of these cases. Two cases involved posterior circulation @entity2850 , and one case involved @entity455 and its relation to @entity439 formation and @entity397 . The @entity1 in Case 1 was a 66-year-old @entity1 with a history of @entity1163 resulting from the bilateral vertebral artery becoming occluded when he rotated his head. Successful microsurgical decompression at the skull base resulted in patent bilateral vertebral artery V3 segments upon head movement in all directions. The @entity1 in Case 2 was a 53-year-old @entity1 who underwent elective resection of a right temporal @entity1653 and who experienced postoperative drowsiness, @entity1282 , and mild right-arm @entity2055 . Subsequent MRI demonstrated bilateral posterior inferior @entity1416 . Cerebral angiography showed a single PICA, of extradural origin, supplying both cerebellar hemispheres. The PICA exhibited dynamic extradural compression when the @entity1 rotated her head; the bilateral PICA @entity64 were due to head rotation during surgical positioning. In Case 3, a 37-year-old @entity1 found unconscious in her home had diffuse @entity510 and evidence of a right PICA @entity439 . A right far-lateral craniectomy was performed for @entity439 clipping, and she was found to have a dissecting @entity439 with an associated PICA originating extradurally. There was a shearing phenomenon of the extradural PICA along the dura of the foramen magnum, and this microtraumatic stress imposed on the vessel resulted in a dissecting @entity439 . This series of complex and unusual cases highlights the authors' understanding of vascular pathology of the CCJ and its management.

title: Motion-related XXXX at the craniocervical junction: illustrative case series and literature review.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient', 'man']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['a vascular anomaly']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhage']

entities_list: @entity1416 :: ('MESH:D020762', 'Disease') :: ['cerebel-lar artery (PICA) strokes']

entities_list: @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncopal episodes']

entities_list: @entity2850 :: ('MESH:D009408', 'Disease') :: ['vascular compression syndromes']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningioma']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

answer: @entity455 :: (MESH:D014652,Disease) :: ['vascular abnormalities']


abstract: PURPOSE: The goals of this study were to analyze and compare the major clinical response rates and survival of @entity1 with either measurable or assessable disease status to treatment with systemic chemotherapy. @entity1 AND METHODS: All @entity1 had stage IIIB or IV @entity1149 ( @entity1149 ) and were enrolled onto three consecutive phase III clinical trials. @entity1 were stratified by disease status (measurable or assessable) before randomization to systemic chemotherapy. The three trials were conducted in the setting of a multicenter cooperative oncology group. Composite data were obtained for the three trials. Major clinical responses, time to progression, and survival were analyzed and compared in @entity1 with measurable or assessable disease using standard statistical methods. RESULTS: Four hundred twenty-six @entity1 were enrolled onto the three trials from June 1981 through August 1990. @entity66 was present in 236 @entity1 (55%) and assessable disease in 190 (45%). Each study was well balanced for the number of @entity1 with measurable or assessable disease on either treatment regimen. A major clinical response was observed in 71 @entity1 with measurable disease (30%; 95% confidence interval [CI], 24 to 36). Forty @entity1 with assessable disease responded to treatment (21%; 95% CI, 16 to 28) (P = .04). The time to progression for all @entity1 (P = .23) and for responders only (P = .10) was not significantly different based on disease status. Overall survival and survival of responders only was not significantly different, but @entity1 with assessable disease tended to do better. Using multivariate analysis, sex and disease status had a borderline influence on the major response rate (P = .05). Performance score (PS) was the only factor that was significantly correlated with survival. CONCLUSION: @entity1149 @entity1 with assessable disease have major clinical response rates, time to progression, and survival that are similar to those of @entity1149 @entity1 with measurable disease. This study supports the inclusion of @entity1 with @entity2 in both phase II and III trials conducted in the cooperative group setting.

title: Measurable or assessable disease in XXXX trials: does it matter?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Measurable disease']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['assessable-disease lung cancer']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung cancer']


abstract: AIMS: @entity461 ( @entity461 ) promotes @entity460 reabsorption in the cortical distal nephron (CDN). The @entity1391 concentration ([P]f) rises in that segment in @entity740 ( @entity740 ); in theory, high [P]f could reduce availability of @entity460 for reabsorption and necessitate a compensatory rise in [ @entity461 ]. With assumptions, [P]f is proportional to @entity1391 excreted/volume of filtrate (EP/GFR). We therefore hypothesized that [ @entity461 ] would correlate with EP/GFR in @entity740 , and /\ @entity461 ] would correlate with /\EP/GFR after sevelamer therapy. METHODS: We conducted a 4-week, placebo-controlled trial of sevelamer @entity6445 in @entity1 with @entity740 . [ @entity461 ]1-84 and parameters of @entity1391 homeostasis were measured before and after treatment. GFR was assumed to equal @entity1011 clearance (Ccr). Pertinent linear regressions were performed. RESULTS: @entity1391 excretion fell in the sevelamer group only. Decrements in [ @entity461 ] with sevelamer differed from increments with placebo. With either treatment, [ @entity461 ] correlated with EP/Ccr and /\ @entity461 ] correlated with /\EP/Ccr. Changes in [ @entity461 ] were minimal in some sevelamer recipients despite reductions in EP/Ccr; @entity460 excreted/volume of filtrate was low in these subjects. CONCLUSIONS: @entity1391 influx affected [ @entity461 ] in @entity740 by determining [P]f in the CDN. In some @entity1 , low @entity460 influx may have blunted the effect of sevelamer on [ @entity461 ].

title: Use of sevelamer to examine the role of intraluminal XXXX in the pathogenesis of secondary hyperparathyroidism.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6445 :: ('CHEBI:41609', 'Chemical') :: ['carbonate']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']

entities_list: @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate', 'Phosphate']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity461 :: ('5741', 'Gene') :: ['PTH', 'Parathyroid hormone']

answer: @entity1391 :: (CHEBI:26020,Chemical) :: ['phosphate']


abstract: @entity1 with severe @entity447 or @entity2880 have recurrent joint bleedings, which can occur spontaneously or as a result of @entity130 . Resorption of intraarticular blood induces an @entity32 of the synovium and @entity16 , finally leading to severe changes of the joint with complete destruction. This process is called @entity2720 . After failure of substitution and intensive conservative therapy after 3 to 6 months, a synovectomy or a synoviorthesis are indicated. In some cases the progression of @entity2720 cannot be stopped and requires @entity2720 . In some cases joint motion cannot be saved and requires arthrodesis. This paper presents methods and results of different operation concepts in @entity1 (n = 39) with @entity447 or @entity2880 . Especially by implanting total knee (n = 17) and total @entity572 (n = 6) we obtained very good functional results after an average follow-up period of 33.3 respectively 56.3 months. In a series of synovectomie of the knee performed before 1990 (n = 7) and followed after an average period of 21.4 years the progression of @entity2720 could not be stopped. In a second series of synovectomy of the knee performed after 1990 (n = 5) and follow after an average period of 5.6 years, at least the mobility of the knee could be saved. Only one @entity1 of a series of supra- and infracondylar osteotomie (n = 9) achieved the wanted result. Further we performed 6 operations on the hindfoot with satisfying results.

title: [Orthopedic interventions in XXXX with @entity447 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity447 :: ('MESH:D006467', 'Disease') :: ['hemophilia', 'hemophilia A']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['cartilage damage']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['hip joints']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['total joint arthroplasty', 'hemophilic arthropathy']

entities_list: @entity2880 :: ('MESH:D014842', 'Disease') :: ['von-Willebrand-syndrome', 'B and von Willebrand Syndrome']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Visual inspection of cervix after application of @entity1543 (VIA) is an effective screening tool for @entity5 in low resource settings, but its low specificity leads to high referral rates. Adjunctive testing may overcome this drawback. AIMS: This pilot study was aimed to assess test performances of VIA, @entity1082 ) testing and @entity975 smear, individually and in simulated combinations, to determine the probable best screening option. SETTING AND DESIGN: Gynecology outpatient department (OPD); cross-sectional study. MATERIALS AND METHODS: One hundred @entity1 with complaints of irregular @entity3556 or discharge, post @entity548 or unhealthy cervix on examination underwent @entity975 smear, HPV testing, VIA, colposcopy and biopsy, if indicated, in this screening order. STATISTICAL ANALYSIS: Sensitivity, specificity, positive predictive value ( @entity2286 ) and negative predictive value (NPV) were calculated for each of the tests with a biopsy result of > or =HSIL taken as the gold standard. Simulated parallel and sequential combinations for VIA/ @entity975 , VIA/HPV and HPV/ @entity975 were calculated and compared with individual test performance. RESULTS: Prevalence of abnormal @entity975 smears was 5%, VIA positive 51% and HPV positive 16%. Sensitivity and specificity of VIA were 100% and 53.3% respectively. For HPV and @entity975 tests corresponding figures were 85.7%, 89.7% and 50%, 98.9% respectively. The best simulated combination with a balance of sensitivity and specificity was of VIA followed by HPV testing (sensitivity 85.7%, specificity 95.4%). CONCLUSION: Addition of HPV testing to VIA can increase the specificity of VIA, thereby reducing the referral rates without compromising the sensitivity of the test.

title: Evaluation of adjunctive tests for XXXX screening in low resource settings.

entities_list: @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['coital bleeding']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

entities_list: @entity1543 :: ('MESH:D019342', 'Chemical') :: ['acetic acid']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: AIMS: The BRANCH study was a prospective, multicentre, non-randomised, single arm trial to investigate the feasibility, safety, efficacy, and performance of the bare metal Medtronic Bifurcation Stent System for the treatment of de novo @entity75 . METHODS AND RESULTS: Sixty @entity1 were enrolled in the study. After a learning curve of one case at seven centres, 53 @entity1 from six centres were prospectively treated. The primary endpoint was @entity177 ( @entity177 ) at 30 days. Secondary endpoints included acute device, lesion, and procedure success and @entity177 at 12 months. Medina complex @entity75 (1,1,1; 1,1,0; 1,0,1; 0,1,1) were treated in 71.7%. The stent was successfully implanted in 86.8% of cases. Acute device, lesion, and procedure success rates were 83.0%, 92.5%, and 88.7%, respectively. @entity177 occurred in 2/52 @entity1 (3.8%) at 30 days. No other major adverse cardiac adverse events (MACE) occurred through 30 days follow-up. At 12 months, @entity177 occurred in 6/47 (12.8%) @entity1 , and MACE occurred in 5/47 (10.6%) @entity1 . CONCLUSIONS: Results from the BRANCH study demonstrate that the Medtronic Bifurcation Stent System is safe and can be successfully and effectively deployed in a variety of @entity75 with good clinical outcomes.

title: First-in- XXXX experience with the Medtronic Bifurcation Stent System.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['bifurcation lesions']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['target vessel failure', 'TVF']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: UNASSIGNED: Abstract Cough and upper airway @entity113 are well-recognized adverse reactions of angiotensin-converting enzyme inhibitor (ACEI) therapy. @entity113 is an infrequent and often unrecognized complication of ACEI therapy. We describe a @entity1 in whom the diagnosis was delayed for > 2 years. A 60-year-old @entity1 with @entity101 on treatment with @entity4688 presented with complaints of @entity490 and @entity294 for 2 days. Physical examination was significant for diffuse abdominal tenderness and @entity551 . Laboratory data were normal except for @entity491 and elevated @entity1011 . Computed tomography (CT) of the abdomen showed diffuse small bowel wall thickening. ACEI-induced visceral @entity113 was considered, @entity4688 was discontinued and supportive care was provided. @entity1 's symptoms and CT appearance improved 48 and 72 hours, respectively, after stopping @entity4688 . She remained symptom-free 1 year after discharge.

title: XXXX : an under-recognized complication of angiotensin-converting enzyme inhibitors.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient', 'Patient']

entities_list: @entity4688 :: ('MESH:D004656', 'Chemical') :: ['enalapril']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity113 :: ('MESH:D000799', 'Disease') :: ['Visceral angioedema', 'angioedema']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity491 :: ('MESH:D007964', 'Disease') :: ['leukocytosis']

answer: @entity113 :: (MESH:D000799,Disease) :: ['Visceral angioedema']


abstract: In @entity3377 , @entity227 due to optic nerve involvement is rare, and acute onset @entity227 is an unusual presenting feature. We report a 15-y-old @entity1 who had @entity3043 and who was admitted to our hospital with acute onset of @entity1939 and @entity221 . There was no light perception, and anterior segment and fundus examination were normal in both eyes. No other abnormal neurological findings were detected. Increased latencies and decreased amplitudes were found in visual evoked potentials. Cranial MR and CT revealed no abnormality. Blood culture was found to be positive for Brucella melitensis. Anti-Brucella treatment and high-dose metil prednisolon were given. @entity3043 completely resolved 5 d after anti-Brucella treatment, and at the end of the third month her complaints about @entity227 were resolved. CONCLUSION: Brucellosis may present with uncommon symptoms in @entity1 . Physicians, particularly in areas where the disease is endemic, must consider this in differential diagnosis of a @entity1 with acute @entity1939 and @entity3043 .

title: Unusual presentation of @entity3377 in a @entity1 : acute XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'girl', 'child']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual loss', 'impaired vision', 'visual impairment']

entities_list: @entity3377 :: ('MESH:D002006', 'Disease') :: ['brucellosis']

entities_list: @entity1939 :: ('MESH:D001766', 'Disease') :: ['bilateral blindness', 'blindness']

entities_list: @entity3043 :: ('MESH:D010198', 'Disease') :: ['Pancytopenia', 'pancytopenia']

answer: @entity1939 :: (MESH:D001766,Disease) :: ['blindness']


abstract: The suprachiasmatic nucleus (SCN) of the hypothalamus is responsible for generating circadian rhythms in mammals, and @entity1246 is the predominant neurotransmitter in the SCN. Properties of @entity1246 -A (GABAA) responses in SCN neurons were examined in acutely prepared hypothalamic slices from 3- to 8-wk-old @entity35 with the use of whole cell voltage-clamp techniques. @entity8862 reduced the amplitude of GABAA-mediated spontaneous inhibitory postsynaptic currents (sIPSCs) in a concentration-dependent manner ranging from a reduction of control amplitude to 88% at 10 microM to 27% at 1,000 microM. @entity8862 reduced IPSC amplitude to a similar degree in the presence of @entity1022 and also significantly reduced the amplitude of currents evoked by application of exogenous @entity1246 (100 microM, pressure applied). @entity8862 increased the frequency of IPSCs at lower concentrations and decreased it at higher ones. @entity12029 (100 nM) usually failed to potentiate the amplitude of sIPSCs, but prolonged sIPSC kinetics. Two exponential components were normally resolved in the sIPSC decay constants, and @entity12029 significantly increased those two components. Thus @entity12029 increased the duration of sIPSCs and potentiated the amplitude of currents evoked by pressure application of @entity1246 . @entity8862 and @entity1245 each modulated the effect of @entity1246 in nearly all cells, suggesting that most SCN neurons have a similar GABAA receptor subunit composition in this respect. @entity8862 also affected sIPSC frequency, which suggests that @entity8862 increased neuronal firing rate at lower concentrations. These results begin to define the cellular roles that these GABAA receptor modulators might play in circadian regulation.

title: Zinc and @entity12029 modulation of @entity1246 -mediated currents in XXXX suprachiasmatic neurons.

entities_list: @entity12029 :: ('MESH:D005445', 'Chemical') :: ['Flunitrazepam', 'flunitrazepam']

entities_list: @entity1246 :: ('MESH:D005680', 'Chemical') :: ['gamma-aminobutyric acid', 'GABA']

entities_list: @entity1022 :: ('MESH:D013779', 'Chemical') :: ['tetrodotoxin']

entities_list: @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepine']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: INTRODUCTION: @entity2023 can cause changes in stomatognathic functions, which may alter the mandibular dynamics. Electrognathography is used in the recording of @entity89 , making it valid for analysis of movements in speech. PURPOSE: To characterize the amplitude and velocity of @entity89 during speech in @entity1 with and without @entity2023 . METHODS: The sample consisted of 32 @entity1 aged 7-12 years, treated at a university hospital, divided into two groups: one with @entity2490 and the other without @entity2490 . To capture the @entity89 during speech, we used an electrognathography with the aid of a list of phonetically balanced figures. For the analysis of data, we used, in addition to descriptive statistics, nonparametric tests, Spearman correlation coefficient and the Mann-Whitney test, with a significant value of p=0.05. RESULTS: No significant difference was observed in @entity89 between groups, with values of p equals to 0.175, 0.650, and 0.462 for amplitude and jaw opening and closing velocity, respectively. However, a strong correlation was observed between the variables velocity and amplitude of mouth opening, being slightly higher in the group of @entity1 with @entity2023 . CONCLUSION: The amplitude and velocity of @entity89 are found to be similar in @entity1 with and without @entity2023 , and a correlation exits between these variables. In addition, they were more heterogeneous in the group without @entity2023 .

title: Jaw movement during the speech in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity89 :: ('MESH:D007571', 'Disease') :: ['jaw movements']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['Allergic rhinitis', 'allergic rhinitis']

answer: @entity2023 :: (MESH:D006255,Disease) :: ['allergic rhinitis']


abstract: Numerous studies have demonstrated the efficacy of the Adeno-Associated Virus (AAV)-based gene delivery platform in vivo. The control of transgene expression in many protocols is highly desirable for therapeutic applications and/or safety reasons. To date, the @entity803 and the @entity3446 dependent regulatory systems have been the most widely evaluated. While the long-term regulation of the transgene has been obtained in rodent models, the translation of these studies to larger animals, especially to nonhuman primates (NHP), has often resulted in an immune response against the recombinant regulator protein involved in transgene expression regulation. These immune responses were dependent on the target tissue and vector delivery route. Here, using AAV vectors, we evaluated a @entity47931 -inducible system in rodents and macaques in which the TetR protein is fused to the @entity1 Kr  ppel associated box (KRAB) protein. We demonstrated long term gene regulation efficiency in rodents after subretinal and intramuscular administration of @entity21481 and @entity21481 vectors, respectively. However, as previously described for other chimeric transactivators, the TetR-KRAB-based system failed to achieve long term regulation in the macaque after intramuscular vector delivery because of the development of an immune response. Thus, immunity against the chimeric transactivator TetR-KRAB emerged as the primary limitation for the clinical translation of the system when targeting the skeletal muscle, as previously described for other regulatory proteins. New developments in the field of chimeric drug-sensitive transactivators with the potential to not trigger the host immune system are still needed.

title: Transgene Regulation Using the XXXX -Inducible TetR-KRAB System after AAV-Mediated Gene Transfer in Rodents and Nonhuman Primates.

entities_list: @entity47931 :: ('CHEBI:50845', 'Chemical') :: ['doxycyclin']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['rapamycin']

entities_list: @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline']

answer: @entity803 :: (MESH:D013752,Chemical) :: ['Tetracycline']


abstract: This report examines the case of a 45 year-old married @entity1 suffering from @entity66440 with @entity129 and generalized lymphadenopathy -- a rare clinical expression in the present antibiotic @entity7971 . On March 3, 1988, the individual sought assistance a month after first noticing an @entity1066 genitalia. He also complained of @entity10 , watering, and the inability to close his right eye. Though previously free of any STD, the @entity1 was promiscuous, having exposures to prostitutes off and on. Upon a genital examination, physicians discovered over the coronal sulcus a large, solitary, nontender, nonbleeding, indurated, pinkish @entity1066 oozing serum. Besides excessive lacrimation and the inability to close the right eye, the examiners noticed a deviation of the angle of the mouth towards the left side and Bell's sign. A series of tests indicated that the @entity1 was suffering from syphilis. Following the diagnosis, he received injections of @entity16630 for a period of 21 days. Although she did not show any clinical or serological evidence of syphilis, the individual's wife also received treatment for syphilis. 45 days after the beginning of specific therapy, the @entity1 's @entity1066 had healed completely. The @entity3541 had recovered completely after 2 weeks.

title: Early syphilis with XXXX : a case report.

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['seventh nerve palsy']

entities_list: @entity66440 :: ('MESH:C536772', 'Disease') :: ['primary syphilis']

entities_list: @entity16630 :: ('MESH:D010402', 'Chemical') :: ['procaine penicillin']

entities_list: @entity3541 :: ('MESH:D005158', 'Disease') :: ['facial palsy']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches']

answer: @entity129 :: (MESH:D003389,Disease) :: ['seventh nerve palsy']


abstract: Sera from 47 angiography @entity1 were included in medium supporting the growth of @entity1 arterial smooth muscle-derived cells (HUSMC). Ten sera from the 38 @entity1 demonstrating significant @entity453 caused marked cellular accumulation of neutral lipid, causing the cultured cells to resemble the foam cells of @entity731 . None of the sera from the 9 non- @entity731 @entity1 caused such marked @entity1560 . A lesser degree of lipid accumulation by the cultured cells was seen for 4/38 @entity731 and 2/9 non- @entity731 @entity1 sera. The cell lipids were analyzed by thin layer chromatography and were shown to be @entity412 (TG). The quantities of neutral lipids which accumulated in cultured HUSMC were estimated by absorbances due to Oil red O staining of lipid which were normalized to total cell protein based on absorbances due to Coomassie brilliant blue G-250 staining, yielding specific lipid content index values. Serum nonesterified @entity1718 ( @entity3691 ) concentrations and @entity3691 /albumin molar ratios were strongly and significantly correlated with specific lipid content index values (r = 0.870, P less than 0.001; r = 0.001, respectively), while total @entity165 and TG concentrations did not yield significant associations. The observed @entity1560 could be reproduced in HUSMC by the addition of exogenous @entity3691 to the culture medium. Measurements of proliferation of the cultured HUSMC showed no differences between sera causing lipid accumulation and sera lacking this effect. It is suggested that circulating @entity3691 concentrations may play a role in the etiology of @entity731 .

title: Sera containing elevated nonesterified @entity1718 from @entity1 with angiographically documented @entity453 cause marked lipid accumulation in cultured XXXX arterial smooth muscle-derived cells.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity1560 :: ('MESH:D005234', 'Disease') :: ['steatosis']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerotic plaque']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery obstruction']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The degree of @entity75 associated with high-level fluid-percussion injury (3.0 to 3.8 atm) was investigated in anesthetized @entity468 . Measurements were made of the animals' intracranial pressure (ICP) pressure-volume index (PVI), far-field brain-stem auditory evoked responses (BAER's), and cerebral blood flow (CBF). The animals were classified into two groups based on the severity of @entity16 to the brain stem after @entity130 : Group 1 had mild intraparenchymal and @entity510 and Group 2 had severe intraparenchymal and @entity510 . The ICP values in Group 1 were insignificantly lower than those in Group 2, while the PVI values in Group 2 were clearly lower (p less than 0.05). Immediately after the injury, peaks II, III, and IV of the BAER's demonstrated a transitory and marked suppression. One Group 1 and two Group 2 animals showed the disappearance of peak V. In Group 1, the latencies of peak II, III, and IV gradually increased until 60 to 150 minutes postinjury, then returned to 95% of baseline value at 8 hours; however, the animals in Group 2 showed poor recovery of latencies. Two hours after @entity1545 , the CBF decreased to 40% of the preinjury measurement in both groups (p less than 0.001). In contrast to Group 2, the CBF in Group 1 returned to 86.8% of the preinjury measurement by 8 hours following the injury. Changes in PVI, BAER, and CBF correlated well with the degree of @entity1545 following severe @entity542 . These data indicate that high-level fluid-percussion injury (greater than 3.0 atm) is predominantly a model of @entity1545 .

title: Evaluation of @entity75 following severe fluid-percussion XXXX to the cat.

entities_list: @entity1545 :: ('MESH:D020214', 'Disease') :: ['brain injury', 'brain-stem injury']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhages']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain-stem dysfunction']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathological damage']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury']

answer: @entity542 :: (MESH:D006259,Disease) :: ['head injury']


abstract: In January 1991 a severe @entity3082 of @entity3081 started in Peru, a country located north of Chile. The first case in Chile was confirmed in april and so far 41 cases and 2 @entity204 have been reported. The @entity3082 is caused by @entity1838 01, El Tor biotype, Inaba serotype. Most cases occurred in Santiago, 2/3 of them in @entity1 and all above 15 years of age. An unknown number of asymptomatic infected @entity1 arriving in Santiago are the likely agents for the @entity3082 . Contamination of sewage and use of infected water to irrigate vegetable fields is involved in the transmission of the disease. The situation is linked to the inexistence of sewage treatment plants. In comparison to Peru, with near 200,000 @entity1 and over 1000 @entity204 , the @entity3082 in Chile has been small as a consequence of intensive health education efforts. Personal hygiene, abstinence from eating raw vegetables and fish, destruction of presumed infected crops, and prohibition of vegetable transportation to other areas have been the cornerstone of the preventive strategies. Early treatment of severely @entity2700 @entity1 has determined a low fatality rate. At present, the @entity3082 is virtually controlled with 1 or 2 cases a week. However, the sanitary problems related to sewage treatment and the existence of @entity3081 in other South American countries poses a serious problem for the future.

title: [Epidemic of XXXX in Chile; 1991].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people', 'men']

entities_list: @entity2700 :: ('MESH:D003681', 'Disease') :: ['dehydrated']

entities_list: @entity1838 :: ('666', 'Species') :: ['Vibrio cholerae']

answer: @entity3081 :: (MESH:D002771,Disease) :: ['cholera']


abstract: UNASSIGNED: @entity4224 is a primary vector of dengue and @entity12517 . The use of synthetic insecticides to control Aedes populations often leads to high operational costs and adverse non-target effects. Botanical extracts have been proposed for rapid extracellular synthesis of mosquitocidal nanoparticles, but their impact against predators of mosquito larvae has not been well studied. We propose a single-step method for the biosynthesis of @entity575 nanoparticles (AgNP) using the extract of Artemisia vulgaris leaves as a reducing and stabilizing agent. AgNP were characterized by UV-vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), @entity4653 ( @entity4653 ), energy-dispersive X-ray spectroscopy (EDX), and @entity11898 ( @entity11898 ). @entity4653 and @entity11898 showed that AgNP were polydispersed, crystalline, irregularly shaped, with a mean size of 30-70  nm. EDX confirmed the presence of elemental @entity575 . FTIR highlighted that the functional groups from plant metabolites capped AgNP, stabilizing them over time. We investigated the mosquitocidal properties of A. vulgaris leaf extract and green-synthesized AgNP against larvae and pupae of Ae. aegypti. We also evaluated the predatory efficiency of Asian bullfrog tadpoles, @entity36804 , against larvae of Ae. aegypti, under laboratory conditions and in an aquatic environment treated with ultra-low doses of AgNP. AgNP were highly toxic to Ae. aegypti larval instars (I-IV) and pupae, with LC50 ranging from 4.4 (I) to 13.1  ppm (pupae). In the lab, the mean number of prey consumed per tadpole per day was 29.0 (I), 26.0 (II), 21.4 (III), and 16.7 (IV). After treatment with AgNP, the mean number of mosquito prey per tadpole per day increased to 34.2 (I), 32.4 (II), 27.4 (III), and 22.6 (IV). Overall, this study highlights the importance of a synergistic approach based on biocontrol agents and botanical nano-insecticides for mosquito control.

title: Predation by Asian bullfrog tadpoles, XXXX , against the dengue vector, @entity4224 , in an aquatic environment treated with mosquitocidal nanoparticles.

entities_list: @entity12517 :: ('MESH:D065632', 'Disease') :: ['chikungunya']

entities_list: @entity11898 :: ('MESH:C564523', 'Disease') :: ['XRD', 'X-ray diffraction']

entities_list: @entity4224 :: ('7159', 'Species') :: ['Aedes aegypti']

entities_list: @entity36804 :: ('103373', 'Species') :: ['Hoplobatrachus tigerinus']

entities_list: @entity4653 :: ('MESH:D004401', 'Disease') :: ['SEM', 'scanning electron microscopy']

answer: @entity36804 :: (103373,Species) :: ['Hoplobatrachus tigerinus']


abstract: UNASSIGNED: Gamma knife surgery (GKS) is now used as a treatment option for @entity5587 ( @entity5587 ). Most authors have selected the distal part of the nerve as the gamma knife target. Here we report on 3 @entity1 with medically intractable @entity5587 who were treated with GKS. All 3 @entity1 had a single shot with a 4-mm collimator which was used to deliver 80 Gy to the 100% isodose line. The GKS targets were the medial cisternal segments of the glossopharyngeal nerve. @entity1 were investigated prospectively, treated, and then assessed periodically with respect to @entity158 relief and neurological function. Three @entity1 felt @entity158 reduced at 2, 7, and 11 days, respectively. None of them have suffered recurrent @entity158 since becoming @entity158 free. The follow-up after radiosurgery was 25 months, 22 months, and 20 months, respectively. This preliminary experience provides encouraging evidence that choosing the medial cisternal segment of the glossopharyngeal nerve as the target is also an option for the treatment of @entity5587 with stereotactic radiosurgery and is consistent with previous reports. Additional follow-ups and a larger number of @entity1 are needed to demonstrate the long-term safety and effectiveness for this indication.    2015 S. Karger AG, Basel.

title: Gamma Knife Radiosurgery for XXXX by Targeting the Medial Cisternal Segment of the Glossopharyngeal Nerve: Report of 3 Cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5587 :: ('MESH:D020435', 'Disease') :: ['glossopharyngeal neuralgia', 'GPN']

answer: @entity5587 :: (MESH:D020435,Disease) :: ['Glossopharyngeal Neuralgia']